Germany – Pharmaceutical products – Conclusion not excluding drug discount agreement. according to Section 130a Paragraph 8 SGB V through an open house model for the active ingredient infliximab for subcutaneous injection (ATC code according to WHO: L04AB02)
TenderZenith matches this tender's eligibility criteria against your company profile to calculate a deterministic qualification score and identify potential disqualifiers.
A structured breakdown of scope, eligibility requirements, submission steps, and key conditions — extracted directly from the official notice.
Sign in to unlock Bid Fit & AI Opportunity Intelligence
TenderZenith calculates a personalized qualification score against your company profile and extracts structured intelligence from tender documents with your 7-Day Pro Trial (No Credit Card Required).
Description & Project Overview
The subject of this publication is the conclusion of non-exclusive discount agreements in accordance with Section 130a Paragraph 8 SGB V for medicinal products with the active ingredient infliximab for subcutaneous injection (ATC code according to WHO: L04AB02). The contract is concluded within the framework of a so-called open house model, i.e. h. The conclusion of a contract is open to all interested pharmaceutical companies within the participation period, provided they meet and accept the participation requirements. This means that individual contract negotiations are not carried out and there is no (delivery) exclusivity
Related Procurement Opportunities
Similar tenders in Healthcare and Medicine, Pharmaceuticals